What Would An EU ‘Regulatory Sandbox’ Bring To New Drug Development?
Executive Summary
Digital health, AI, real-world evidence and “proactive learning” are key components of the EU’s proposals for new ways of regulating novel medicines, but only time will tell which products might benefit from the flexibilities offered by the “regulatory sandbox.”
You may also be interested in...
How The EU & UK’s Contrasting Approaches To AI Regulation Could Impact Pharma
While EU preparations are underway to introduce strict legal requirements for all AI systems, the UK has doubled down on its flexible, non-regulatory framework. In this second of a two-part article, a lawyer explains the pros and cons of each for pharma and medtech firms.
AI Regulation: EU Network Announces Four-Year Action Plan
Multiple guidance documents, a regulatory sandbox, and the creation of an “observatory” to monitor the emergence of new technologies are some of the actions being considered by the European medicines regulatory network under its AI regulatory system workplan.
EU Rapporteur Slams Commission’s ‘Regulatory Sandbox’ & Antimicrobial ‘Voucher’ Proposals
Tiemo Wölken has proposed a public “European Medicines Facility” to elaborate R&D projects focusing on the development of priority antimicrobials and medicines for other unmet medical needs. He also disagrees with his fellow rapporteur’s support for an increase in the regulatory data protection period.